aldafermin
aldafermin: developed by 1 company · 1 clinical trial tracked.
aldafermin evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect aldafermin to NGM; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could aldafermin → NGM affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| NGM BIOPHARMACEUTICALS INC (NGM) | Phase 2/Phase 3 |
Clinical Trials (1)
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of Aldafermin in Subjects With Primary Sclerosing Cholangitis (ALPINE-PSC).
Primary endpoint: Change From Baseline in Enhanced Liver Fibrosis Score at Week 96
InterventionalRandomizedquadruple0 targetStarted 2024-10Completion 2025-03NGM Biopharmaceuticals, Inc
Frequently asked questions
Who is developing aldafermin?
aldafermin is being developed by NGM BIOPHARMACEUTICALS INC.
How many clinical trials involve aldafermin?
BioSniper tracks 1 clinical trial involving aldafermin.